Intramedullary Spinal Cord Metastasis (SCM) From Prostate Carcinoma Detected on [ 68 Ga] Ga-PSMA-11 PET/CT.

Clin Nucl MedMar 25, 2026 (epub)
Case ReportOncology (Medical)Nuclear MedicineRadiology (Diagnostic)

Madhava Reddy Mali, Rahul V Parghane, Sandip Basu

✦ AI-curated · Sources linked

Case in brief

A 70-year-old man with newly detected, untreated prostate carcinoma (Gleason score 10; PSA 25.99 ng/mL) underwent [68Ga]Ga-PSMA-11 PET/CT for initial staging. Imaging showed an avid primary prostatic lesion, metastatic abdominopelvic lymph nodes and skeletal lesions, and focal moderate uptake in the cervical spinal cord, interpreted as intramedullary spinal cord metastasis. The scan therefore identified spinal cord involvement alongside other metastatic disease during initial staging.

What made this case unusual

The spinal cord metastasis was detected in a recently diagnosed, untreated patient, and appeared as focal moderate PSMA uptake on staging PET/CT.

Diagnostic / clinical pearl

Review the spinal cord as well as the usual metastatic sites on PSMA PET/CT; focal uptake may indicate spinal cord involvement.

Source

PubMed · PMID 41945369

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.